Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.64 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | TEK | Q02763 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.56 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.56 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.56 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.56 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17936093 | 0.95 | MAPT (0.74) | MAPTKCNK3LMNAPTGS1MEN1 | |
| SCHEMBL22772362 | 0.91 | RHOC (0.60) | MAPTKCNK3LMNAPTGS1MEN1 | |
| SCHEMBL17818365 | 0.89 | MAPT (0.66) | MAPTKCNK3LMNAPTGS1MEN1 | |
| SCHEMBL22772371 | 0.86 | ABL1 (0.57) | MAPTKCNK3LMNAPTGS1MEN1 | |
| SCHEMBL4286068 | 0.86 | MAPT (0.94) | MAPTKCNK3LMNAPTGS1MEN1 | |
| SCHEMBL3838614 | 0.86 | HDAC1 (0.66) | MAPTKCNK3MEN1KMT2ARAB9A | |
| SCHEMBL22772385 | 0.85 | P2RX1 (0.70) | MAPTKCNK3LMNAPTGS1P2RX1 | |
| SCHEMBL30080659 | 0.85 | KMT2A (0.68) | MAPTLMNAMEN1KMT2AHTT | |
| SCHEMBL4037834 | 0.85 | KMT2A (0.68) | MAPTLMNAMEN1KMT2AHTT | |
| SCHEMBL22683074 | 0.83 | MEN1 (0.65) | MAPTKCNK3LMNAPTGS1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11407745-B2 | Indazole derivatives and pharmaceutical composition for preventing, alleviating or treating cancer containing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-08-09 | — | — | US | disclosed |
| US-20200392127-A1 | NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-12-17 | — | — | US | disclosed |
| US-20200392127-A1 | NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-12-17 | — | — | US | disclosed |
| CN-105431436-B | Pyrrolo [2,3-D ] pyrimidine derivatives, processes for their preparation and their use as kinase inhibitors | 内尔维阿诺医学科学有限公司 | 2017-11-28 | — | — | CN | disclosed |
| EP-2997030-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-08-09 | — | — | EP | disclosed |
| US-9682083-B2 | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-20 | — | — | US | disclosed |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-06-16 | — | — | US | disclosed |
| CN-105431436-A | Pyrrolo [2,3-D ] pyrimidine derivatives, processes for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2016-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | RET, DCK, PRKD2 | MAPT 2327/4885KCNK3 3041/4885LMNA 2868/4885 |
| US-20200392127-A1 | NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME | ABL1, DDR1, ABL2 | MAPT 3839/4885KCNK3 1121/4885LMNA 2346/4885 |
| US-11407745-B2 | Indazole derivatives and pharmaceutical composition for preventing, alleviating or treating cancer containing the same | ABL1, DDR1, ABL2 | MAPT 3859/4885KCNK3 801/4885LMNA 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.